This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 May 15;20(10):2415-6.

doi: 10.1200/JCO.2002.20.10.2415.

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience

Hagop M Kantarjian

PMID: 12011118
DOI: 10.1200/JCO.2002.20.10.2415

Editorial

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience

Hagop M Kantarjian. J Clin Oncol. 2002.

. 2002 May 15;20(10):2415-6.

doi: 10.1200/JCO.2002.20.10.2415.

Author

Hagop M Kantarjian

PMID: 12011118
DOI: 10.1200/JCO.2002.20.10.2415

No abstract available

PubMed Disclaimer

Comment on

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Silverman LR, et al. J Clin Oncol. 2002 May 15;20(10):2429-40. doi: 10.1200/JCO.2002.04.117. J Clin Oncol. 2002. PMID: 12011120 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information